New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 6, 2014
08:06 EDTSTEMStemCells CEO says difficult to understand stock performance last year
StemCells posted a letter to shareholders from its President and CEO Martin McGlynn, stating in part: "As CEO, one of my easiest and most gratifying jobs is to report our persistent progress to you real evidence that StemCells, Inc. continues to be a clear frontrunner. What is more difficult is trying to understand our Company's stock performance for the year just ended. We have reached out to usually well-informed third parties in the analyst and investor communities to help us understand this dynamic, but have been unable to identify anything unusual or particularly enlightening...StemCells, Inc. is in the unique position of concurrently developing novel product candidates for major medical conditions that have thus far defied traditional treatments, in all three components of the CNS: the spinal cord...the eye...and the brain...If we succeed in bringing our HuCNS-SC cells to market for even one of these indications, we believe it will be very meaningful to patients, shareholders and society at large...In 2013, we closed on approximately $54.6M in fresh capital, $29.3M of which is debt, including the committed forgivable loan from the CIRM of up to $19.3M. We start 2014 with a little over $30M in the bank, and we expect to receive the second tranche of non-dilutive funding from the CIRM, again $3.8M, later this month."
News For STEM From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 22, 2015
09:58 EDTSTEMOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Allison Transmission (ALSN) initiated with a Buy at Stifel... Avago (AVGO) initiated with a Buy at Mizuho... Blackstone (BX) initiated with a Positive at Susquehanna... Cellectis (CLLS) initiated with an Outperform at Oppenheimer... Cypress Semiconductor (CY) initiated with a Buy at Mizuho... Esperion (ESPR) initiated with a Sell at Chardan... H&R Block (HRB) initiated with an Overweight at Piper Jaffray... Horizon Pharma (HZNP) initiated with an Outperform at Leerink... M/A-COM (MTSI) initiated with a Buy at Goldman... Meritor (MTOR) initiated with a Hold at Stifel... Micron (MU) initiated with a Buy at Mizuho... Monster Worldwide (MWW) initiated with a Neutral at Piper Jaffray... NXP Semiconductors (NXPI) initiated with a Buy at Mizuho... National Storage (NSA) initiated with a Sector Weight at KeyBanc... ON Semiconductor (ON) initiated with a Buy at Mizuho... Qorvo (QRVO) initiated with a Buy at Goldman... SanDisk (SNDK) initiated with a Neutral at Mizuho... Sharps Compliance (SMED) initiated with a Buy at Stifel... Skyworks (SWKS) initiated with a Buy at Mizuho... StemCells (STEM) initiated with a Buy at Cantor... Synaptics (SYNA) initiated with a Buy at Mizuho... Synergy Pharmaceuticals (SGYP) initiated with a Buy at Canaccord... Texas Instruments (TXN) initiated with a Neutral at Mizuho... TriNet (TNET) initiated with a Neutral at Piper Jaffray... Vascular Biogenics (VBLT) initiated with a Buy at Roth Capital... Verifone (PAY) initiated with an Outperform at Imperial Capital... uniQure (QURE) initiated with an Outperform at Oppenheimer.
May 21, 2015
18:49 EDTSTEMOn The Fly: After Hours Movers
UP AFTER EARNINGS: Hewlett-Packard (HPQ), up 1%. ALSO HIGHER: Autobytel (ABTL), up 14.1% after acquiring Dealix Corporation and Autotegrity from CDK Global (CDK) for $25M and raising fiscal 2015 guidance... StemCells (STEM), up 2.5% after being initiated with a Buy at Cantor... PTC Therapeutics (PTCT), up 2.3% after a Benefit Assessment by Germany's Federal Joint Committee indicated that Translarna provided a benefit for ambulatory patients... CBOE Holdings (CBOE), up 1.6% after raising share repurchase authorization by $100M... Cypress Semiconductor (CY), up 1.2% after being initiated with a Buy at Mizuho. DOWN AFTER EARNINGS: Aeropostale (ARO), down 18.5%... Brocade (BRCD), down 2.1%... Marvell Technology (MRVL), down 2.9% after reporting quarterly results and departure of CFO. ALSO LOWER: Otonomy (OTIC), down 17.7% following report of Phase 2b topline data for OTO-104... Viggle (VGGL), down 18.8% after filing to sell common stock... CEL-SCI (CVM),down 2.7% after announcing a proposed offering of common stock and warrants.
16:05 EDTSTEMStemCells initiated with a Buy at Cantor
Target $2.
May 18, 2015
10:01 EDTSTEMOn The Fly: Analyst Initiation Summary
Subscribe for More Information
07:12 EDTSTEMStemCells initiated with a Buy at H.C. Wainwright
H.C. Wainwright initiated StemCells with a Buy rating and $1 price target. The firm is encouraged by StemCells preliminary data from early trials of dry age-related macular degeneration and chronic spinal cord injuries.
May 14, 2015
08:40 EDTSTEMStemCells announces positive top-line results of HuCNS-SC Phase I/II study
StemCells announced that Dr. Armin Curt, principal investigator, will present a summary of the safety and preliminary efficacy data from the Phase I/II study investigating Human Central Nervous System Stem Cell, or HuCNS-SC, intramedullary transplantation in thoracic spinal cord injury. The summary will be presented today at 10:15 a.m. EDT at the 4th Joint International Spinal Cord Society, or ISCoS, and American Spinal Injury Association, or ASIA, meeting being held in Montreal, Canada. The abstract was selected as one of the top six platform submissions for the conference. The international, open-label, Phase I/II trial evaluated both safety and preliminary efficacy of StemCells, Inc.'s proprietary HuCNS-SC human neural stem cells as a treatment for chronic spinal cord injury. The trial enrolled twelve patients who had suffered injury to the thoracic cord and were in the early chronic stage of recovery. The severity of spinal cord trauma is classified by the ASIA Impairment Scale, or AIS, according to the degree of sensory and motor loss. Patients classified as AIS A, the most severe injury, have lost both sensory and motor function below the level of injury. AIS B patients are considered less severely injured because, although they also have no motor function below the level of injury, some limited sensory function is maintained. The protocol was specifically designed to test safety and preliminary efficacy across this spectrum of injury severity, and ultimately the trial transplanted seven AIS A and five AIS B patients.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use